Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Fabric coating Covid killer HeiQ to join UK stock market

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
When a company makes a claim that its fabric coating kills all known bacteria and viruses including Covid-19 within 30 minutes and has a shelf-life of up to seven years, it tends to get attention.
The Viroblock product from Swiss-based HeiQ Materials was originally developed as an antimicrobial for the Ebola crisis in 2013 and now it is seeing strong demand following the Covid-19 pandemic.
Investors will soon get a chance to buy its shares as HeiQ is coming to the UK stock market on 7 December via a reverse takeover of cash shell Auctus Growth (AUCT:AIM).
Oliver Brown, fund manager of MFM UK Primary Opportunities (B905T77), told Shares that the founders happened upon the antimicrobial opportunity after completing long walks in the Swiss mountains and getting complaints from their wives about the smelly clothes.
In addition to Viroblock, HeiQ has built a presence in textile performance materials that provide enhanced features such as cooling/heating and water repellence.
It boasts blue chip clients such as Swedish company IKEA, luxury goods brand Burberry (BRBY) as well as performance brands North Face, Champion and New Balance.
RC Brown, Premier Miton and Amati Global Investors are among the institutional investors backing the company at the stock market listing.
Amati fund manager David Stevenson says a key attraction is HeiQ’s intellectual property amassed since 2005 including multiple patents and awards for its innovative technologies.
Based on the £140 million valuation at listing, HeiQ will trade at around 3.5 times sales compared to the 7.1 times of infection prevention specialist Tristel (TSTL:AIM), and 4.4 times for antimicrobial products company Byotrol (BYOT:AIM).
The company is forecast to see annual sales grow by 50% in 2021 slowing to 30% in later years. Profit for the first half of 2020 was $8.6 million.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.